Compare A O Smith Corp (AOS) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
A O Smith Corp vs Davita Inc — how do they compare? A O Smith Corp trades at $63.65 (market cap $8.65B), while Davita Inc trades at $179.02 (market cap $11.38B). The key difference: Davita Inc is the larger of the two by market cap, and A O Smith Corp pays a 2.26% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| AOS | DVA | |
|---|---|---|
Market Cap | $8.65B | $11.38B |
Sector | Industrials | Health |
52-Week High | $80.47 | $240.96 |
52-Week Low | $55.78 | $103.87 |
Enterprise Value | $9.15B | $24.10B |
Dividend Yield | 2.26% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About A O Smith Corp
A.O. Smith Corporation manufactures and markets comprehensive lines of residential and commercial gas, gas tankless, and electric water heaters. Supplementary products include water heating equipment, condensing and noncondensing boilers, and water system tanks. The company's two operating segments are by geographic region: North America (majority of total revenue) and the Rest of the World. A material portion of sales in North America derive from replacing existing products, and the company utilizes a wholesale distribution channel and multiple selling locations. The Rest of the World segment sells primarily to Asian countries and operates sales offices to expand distribution and market its product portfolio.
Read more on AOS →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
